296 related articles for article (PubMed ID: 20532787)
1. [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].
Horneff G
Z Rheumatol; 2010 Aug; 69(6):516-26. PubMed ID: 20532787
[TBL] [Abstract][Full Text] [Related]
2. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.
Horneff G; Klein A; Oommen PT; Hospach A; Foeldvari I; Feddersen I; Minden K
Clin Exp Rheumatol; 2016; 34(6):1113-1120. PubMed ID: 27749226
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
Shenoi S; Wallace CA
Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
[TBL] [Abstract][Full Text] [Related]
4. Pediatric rheumatology: JIA, treatment and possible risk of malignancies.
Ruperto N; Martini A
Nat Rev Rheumatol; 2011 Jan; 7(1):6-7. PubMed ID: 21135880
[No Abstract] [Full Text] [Related]
5. [The importance of biologicals in the treatment of SoJIA].
Dückers G; Niehues T
Z Rheumatol; 2010 Aug; 69(6):505-15. PubMed ID: 20668866
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
7. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
Becker I; Horneff G
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
[TBL] [Abstract][Full Text] [Related]
8. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
[TBL] [Abstract][Full Text] [Related]
9. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
Lahdenne P; Vähäsalo P; Honkanen V
Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
[TBL] [Abstract][Full Text] [Related]
10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
11. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
12. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
13. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.
Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU
Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578
[TBL] [Abstract][Full Text] [Related]
14. When should we use TNF antagonists in children with rheumatic disease?
Quartier P
Joint Bone Spine; 2007 Jan; 74(1):1-3. PubMed ID: 17174585
[No Abstract] [Full Text] [Related]
15. [Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience].
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Reumatismo; 2007; 59(3):244-61. PubMed ID: 17898886
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
17. [Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Wörlitzer Expertengespräche 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie].
Horneff G
Z Rheumatol; 2006 Mar; 65(2):152-6, 158. PubMed ID: 16372138
[TBL] [Abstract][Full Text] [Related]
18. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
Southwood TR; Foster HE; Davidson JE; Hyrich KL; Cotter CB; Wedderburn LR; Hull RG; Venning HE; Rahman JK; Cummins CL;
Rheumatology (Oxford); 2011 Jan; 50(1):189-95. PubMed ID: 21047801
[TBL] [Abstract][Full Text] [Related]
19. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry.
Zuber Z; Rutkowska-Sak L; Postępski J; Dobrzyniecka B; Opoka-Winiarska V; Kobusińska K; Gietka P; Osińska V; Turowska-Heydel D; Szczygielska I; Kołodziejczyk B; Świątek-Baczkowska A; Gazda A; Wiland P; Tłustochowicz W; Tuszkiewicz-Misztal E
Med Sci Monit; 2011 Dec; 17(12):SR35-42. PubMed ID: 22129916
[TBL] [Abstract][Full Text] [Related]
20. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].
Minden K; Klotsche J; Niewerth M; Horneff G; Zink A
Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]